Horizon Therapeutics PLC (HZNP)
| Market Cap | 26.31B |
| Revenue (ttm) | 2.56B |
| Net Income (ttm) | 518.16M |
| Shares Out | 225.12M |
| EPS (ttm) | 2.19 |
| PE Ratio | 53.20 |
| Forward PE | 19.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 715,356 |
| Open | 116.89 |
| Previous Close | 116.46 |
| Day's Range | 115.70 - 117.65 |
| 52-Week Range | 66.41 - 117.65 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | 134.75 (+15.7%) |
| Est. Earnings Date | Nov 3, 2021 |
About HZNP
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI ...
Financial Performance
In 2020, HZNP's revenue was $2.20 billion, an increase of 69.26% compared to the previous year's $1.30 billion. Earnings were $389.80 million, a decrease of -31.98%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for HZNP stock is "Buy." The 12-month stock price forecast is 134.75, which is an increase of 15.71% from the latest price.
News
Horizon Therapeutics plc Named to Newsweek's List of the Most Loved Workplaces for 2021
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named to Newsweek's inaugural Most Loved Workplaces list for 2021, ranking among the top 100 companies r...
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced data supporting the long-term efficacy of TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
3 Reasons Why Growth Investors Shouldn't Overlook Horizon Therapeutics (HZNP)
Horizon Therapeutics (HZNP) possesses solid growth attributes, which could help it handily outperform the market.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (ineb...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results from a new analysis of UPLIZNA® (inebilizumab-cdon) in neuromyelitis optica spectrum disorder (NMOSD).
New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
DUBLIN--(BUSINESS WIRE)--New TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2021 financial results will be released on Wednesday, Nov. 3, 2021. Following the announcement, Ho...
Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that is has been named one of the Top 100 Adoption-Friendly Workplaces in the United States by the Dave Thomas Foundation...
New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the T...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced a new analysis of UPLIZNA® (inebilizumab-cdon) for the treatment of NMOSD published in Multiple Sclerosis Journal.
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (N...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced UPLIZNA® (inebilizumab-cdon) data in neuromyelitis optica spectrum disorder (NMOSD) to be presented at ECTRIMS 2021.
Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) will present an overview of its pipeline, including five new development programs for investigational medicines, daxdilimab (HZN-7734) an...
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, ...
Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the agenda for its virtual R&D Day for investors and analysts on Sept. 29, 2021. During the event, Horizon's R&D leadersh...
Horizon Therapeutics plc Announces Data Showing UPLIZNA® (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc announces data for UPLIZNA® (inebilizumab-cdon) in African Americans with neuromyelitis optica spectrum disorder (NMOSD).
Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Wi...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP), in collaboration with MIT Solve, a marketplace for social impact innovation, is proud to announce two winning solutions of this year's H...
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
CHARLOTTESVILLE, Va., Sept. 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential ...
Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Best Workplaces for Women™ list for the first time by Fortune and Great Place to Work®...
Horizon Therapeutics reports record quarter
Tim Walbert, Horizon Therapeutics Chairman and CEO, joins The Exchange to discuss his company's record run and the non-Covid pharmaceuticals the company is working on. For access to live and exclusive v...
3 Reasons Why Horizon Therapeutics (HZNP) Is a Great Growth Stock
Horizon Therapeutics (HZNP) could produce exceptional returns because of its solid growth attributes.
Is Horizon (HZNP) a Great Growth Stock?
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon (HZNP).
Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED
Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.
Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (teprotumumab-trbw) for t...
DUBLIN--(BUSINESS WIRE)--Horizon initiates a clinical trial evaluating TEPEZZA® (teprotumumab-trbw) for the treatment for chronic (inactive) Thyroid Eye Disease (TED).
Here's Why Momentum Investors Will Love Horizon Therapeutics (HZNP)
Does Horizon Therapeutics (HZNP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Is Horizon Therapeutics (HZNP) Up 3.7% Since Last Earnings Report?
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?